6 terminated, 3 completed. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Terminated 6, Completed 3 |
Follow tabalumab: new trials by email Literature Review of tabalumab trials Research Report on tabalumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Tabalumab Auto-Injector, Tabalumab Prefilled Syringe - Lupus Erythematosus, Systemic | Phase 3 | Terminated | Eli Lilly and Company | 226 | 2014-01-01 | 2018-06-15 |
| Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA) Tabalumab Auto-Injector, Tabalumab Prefilled Syringe - Rheumatoid Arthritis | Phase 3 | Terminated | Eli Lilly and Company | 8 | 2012-09-01 | 2018-04-26 |
| On Open-Label Study in Participants With Systemic Lupus Erythematosus LY2127399, Placebo - Systemic Lupus Erythematosus, Connective Tissue Disease | Phase 3 | Terminated | Eli Lilly and Company | 1518 | 2012-01-01 | 2018-05-17 |
| An Open Label Study for Participants With Rheumatoid Arthritis LY2127399 - Rheumatoid Arthritis | Phase 3 | Terminated | Eli Lilly and Company | 1086 | 2011-06-01 | 2018-06-11 |
| A Rheumatoid Arthritis Study in Participants LY2127399, Placebo - Rheumatoid Arthritis | Phase 3 | Completed | Eli Lilly and Company | 1004 | 2011-01-01 | 2018-04-25 |
| A Study of LY2127399 in Participants With Systemic Lupus Erythematosus LY2127399, Placebo every 2 weeks, Placebo every 4 weeks - Systemic Lupus Erythematosus, Connective Tissue Disease | Phase 3 | Completed | Eli Lilly and Company | 1124 | 2011-01-01 | 2018-07-17 |
| A Study in Participants With Rheumatoid Arthritis LY2127399, Placebo Q4W, Placebo Q2W - Rheumatoid Arthritis | Phase 3 | Terminated | Eli Lilly and Company | 456 | 2011-01-01 | 2018-05-14 |
| A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate LY2127399, Placebo Q2W, Placebo Q4W - Rheumatoid Arthritis | Phase 3 | Terminated | Eli Lilly and Company | 1041 | 2010-12-01 | 2018-05-08 |
| A Study of LY2127399 in Participants With Systemic Lupus Erythematosus LY2127399, Placebo every 2 weeks, Placebo every 4 weeks - Systemic Lupus Erythematosus, Connective Tissue Disease | Phase 3 | Completed | Eli Lilly and Company | 1164 | 2010-12-01 | 2018-06-12 |
Arthritis, Rheumatoid (5) · Lupus Erythematosus, Systemic (4) · Autoimmune Diseases (3) · Connective Tissue Diseases (3) · Immune System Diseases (3)
United States (9) · Argentina (6) · Poland (6) · Russia (6) · South Korea (6) · Australia (5) · Colombia (5) · Japan (5) · Malaysia (5) · Mexico (5) · New Zealand (5) · South Africa (5) · Taiwan (5) · Brazil (4) · Bulgaria (4)
PMID 27220348, PMID 27723281, PMID 29045736, PMID 31790472, PMID 35947992, PMID 38676311, PMID 25873635, PMID 26293163, PMID 26338095, PMID 26535134, PMID 33687069